Basilea Pharmaceutica Ltd., of Basel, Switzerland, said the FDA disclosed a public meeting of the Anti-Infective Drugs Advisory Committee to discuss the new drug application for the antifungal isavuconazole, which was submitted by a subsidiary of Basilea's licensing partner Astellas Pharma Inc., of Tokyo.